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Introduction and objectives: Evidence for the efﬁcacy and safety of oral anticoagulation with
dicumarines in patients with atrial ﬁbrillation (AF) on hemodialysis is controversial. The
aim  of our study is to evaluate the long-term prognostic implications of anticoagulation
with dicumarines in a cohort of patients with non-valvular AF on a hemodialysis program
due  to end-stage renal disease.
Methods: Retrospective, observational study with consecutive inclusion of 74 patients with
AF  on hemodialysis. The inclusion period was from January 2005 to October 2016. The pri-
mary variables were all-cause mortality, non-scheduled readmissions and bleeding during
follow-up.
Results: Mean age was 75 ± 10 years; 66.2% were men and 43 patients (58.1%) received
acenocoumarol. During a median follow-up of 2.40 years (IQR = 0.88–4.15), acenocoumarolshowed no survival beneﬁt [HR = 0.76, 95% CI (0.35–1.66), p = 0.494]. However, anticoagulated
patients were at increased risk of recurrent cardiovascular hospitalizations [IRR = 3.94, 95%
041]. There was a trend toward an increase in repeated hospitaliza-CI  (1.06–14.69), p = 0.tions  of ischemic cause in anticoagulated patients [IRR = 5.80, 95% CI (0.86–39.0), p = 0.071].
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There was a statistical trend toward a higher risk of recurrent total bleeding in patients
treated with acenocoumarol [IRR = 4.43, 95% CI (0.94–20.81), p = 0.059].
Conclusions: In this study, oral anticoagulation with acenocoumarol in patients with AF on
hemodialysis did not increase survival. However, it was associated with an increased risk
of  hospitalizations of cardiovascular causes and a tendency to an increased risk of total
bleeding.
©  2018 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Introducción y objetivos: La evidencia de la eﬁcacia y seguridad de la anticoagulación oral con
dicumarínicos en pacientes en hemodiálisis con ﬁbrilación auricular (FA) es controvertida.
El  objetivo de nuestro estudio es evaluar las implicaciones a nivel pronóstico a largo plazo
de  la anticoagulación con dicumarínicos en una cohorte de pacientes con FA no valvular en
programa de hemodiálisis debido a insuﬁciencia renal terminal.
Métodos: Estudio observacional retrospectivo con inclusión consecutiva de 74 pacientes en
hemodiálisis con FA. El periodo de inclusión fue de enero de 2005 a octubre de 2016. Las
variables principales fueron mortalidad por todas las causas, reingresos no programados y
sangrados.
Resultados: La edad media fue de 75 ± 10 an˜os; el 66,2% fueron hombres y 43 pacientes (58,1%)
recibieron acenocumarol. Durante una mediana de seguimiento de 2,40 an˜os (IQR = 0,88-
4,15), el acenocumarol no demostró beneﬁcio en supervivencia [HR = 0,76, IC 95% (0,35-1,66),
p  = 0,494]. Sin embargo, los pacientes anticoagulados presentaron más  riesgo de hospital-
izaciones cardiovasculares recurrentes [IRR = 3,94, IC 95% (1,06-14,69), p = 0,041]. Hubo una
tendencia a un aumento de hospitalizaciones repetidas de causa isquémica en los pacientes
anticoagulados [IRR = 5,80, IC 95% (0,86-39,0), p = 0,071]. Se observó una tendencia estadística
hacia un mayor riesgo de sangrados totales recurrentes en los anticoagulados [IRR = 4,43, IC
95%  (0,94-20,81), p = 0,059].
Conclusiones: En el presente estudio, la anticoagulación oral con acenocumarol en pacientes
en  hemodiálisis con FA no supuso un aumento de la supervivencia, y sin embargo, se asoció
con  un mayor riesgo de hospitalizaciones de causa cardiovascular y una tendencia a mayor
riesgo de sangrados totales.
©  2018 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
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were excluded. A total of 74 hemodialysis patients with AF
were included. The decision to treat with oral anticoagula-ntroduction
atients on hemodialysis show a higher prevalence of atrial
brillation (AF) than the general population.1 The CHA2DS2-
ASc score has been widely validated to guide on the need
or anticoagulation therapy for prevention of thromboem-
olic events in non-valvular AF in the general population.2
ue to the prevalence of heart failure, hypertension and
iabetes mellitus, most patients on hemodialysis with AF
ould require oral anticoagulation based on CHA2DS2-
ASc scale. The efﬁcacy and safety of oral anticoagulation
ith dicoumarin in hemodialysis patients with AF is
ontroversial.3–5In the present study, we intend to evaluate the long-term
rognostic implications of anticoagulation with antivitamin Kby-nc-nd/4.0/).
drugs in a cohort of patients on maintenance of hemodialysis
with non-valvular AF.
Methods
Patient  population  and  Study  design
This is a retrospective observational study. From January 2005
to October 2016 all patients from our center hemodialysis pro-
gram with AF were added consecutively to the study. Patients
with mechanical prostheses and signiﬁcant mitral stenosistion was based on the medical criteria of the nephrologist
and/or cardiologist responsible for the care of each patient.
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Table 1 – Baseline characteristics of hemodialysis
patients with non-valvular atrial ﬁbrillation and atrial
ﬂutter. Anticoagulated versus those not anticoagulated.
OAC (n=43) Non-OAC (n=31) p
Gender 13 (30)♀ 12 (38.7)♀ 0.44
Age 74.7 (8) 75.5 (12.7) 0.76
HTN 36 (83.7) 27 (87.1) 0.75
Diabetes 18 (42) 13 (42) 0.99
Ischemic cardiomyopathy 9 (21) 7 (22.6) 0.37
Peripheral vascular disease 7 (15.6) 2 (5.9) 0.28
Previous Ictus 9 (21) 4 (12.9) 0.37
Previous major bleeding 5 (11.6) 2 (6.5) 0.69
Heart failure 10 (23.3) 5 (16.1) 0.45
LVEF ≤40% 7 (16.3) 5 (17.2) 1
CHA2DS2-VASc 4.02 (1.42) 3.48 (1.09) 0.63
HASBLED 3.35 (0.92) 3.48 (1.06) 0.56
Paroxistic 14 (32) 24 (77) 0.001
Persistent 8 (18.6) 5 (16) 0.86
Permanent 21 (48) 2 (6) 0.001
Antiaggregation 3 (7.3) 17 (54.83) 0.001
ACEI o ARA II 13 (25) 13 (33.3) 0.69
Digoxin 12 (23) 2 (5) 0.02
Beta blocker 23 (44) 14 (36) 0.42
Statins 17 (32.7) 9 (23.1) 0.31
LA (mm) 44.7 (6.63) 40.64 (6.64) 0.017
LVH (mm) 10 (24,4) 1 (3) 0.01
Time of follow-up 1015 (854) 1159 (1065) 0.52
Continuous variables are expressed as mean ± standard deviation.
Discrete variables are expressed as a numeric value of %. OAC:
oral anticoagulation; LA: left atrium; ARA II: angiotensin II receptor
antagonists; LVEF: left ventricular ejection fraction; HTN: arterial390  n e f r o l o g i a. 2
The anticoagulant drug administered was acenocoumarol in
all cases.
Data  collection
The clinical information was obtained from the electronic
medical records of the Nephrology and Cardiology depart-
ments containing all data from outpatient and hospital care
are registered. Additional information was extracted from the
Hospital Discharge Program, provided by the Regional Health
Administration mainly containing data of emergency care
episodes and hospitalizations in other units. In anticoagu-
lated patients, the international normalized ratios (INR) and
the therapeutic range times (TRT) were recorded during the
follow-up period; this was accomplished by analyzing the elec-
tronic database of the Hematology Service.
Objectives  and  deﬁnitions
The primary objectives were: all cause mortality, unsched-
uled re-admissions (due to speciﬁc or non-speciﬁc causes) and
bleeding, during follow-up. Hospitalization of a cardiovascular
cause was deﬁned as admissions due to acute coronary syn-
drome, heart failure, stroke, bleeding and peripheral ischemia.
Hospitalizations due to ischemia were hospital admissions
due to cardiac, cerebral or peripheral ischemia. Ischemic
stroke was deﬁned as a neurological deﬁcit of recent onset
that persisted 24 h and was conﬁrmed by imaging techniques
such as computed tomography or magnetic resonance imag-
ing. Major hemorrhages were considered in those cases of
fatal bleeding (with fatal outcome) and those requiring trans-
fusion and/or hospitalization. The follow-up was censored in
the event of death or interruption of anticoagulant treatment
during the follow-up (n = 8).
Statistical  analysis
Continuous variables are presented as mean ± standard
deviation or median [interquartile range (IQR)]. Discrete vari-
ables are shown as percentages. A propensity index (PS) was
generated to minimize potential confounding biases. Those
variables associated with the probability of receiving antico-
agulation with acenocoumarol (p < 0.25 in univariate analysis)
were included in a logistic regression model, creating a ﬁnal
simpliﬁed model using a “backward” covariable selection
algorithm. The ﬁnal model included a set of 12 covariates:
gender, AF/paroxysmal ﬂutter (yes/no), ischemic heart dis-
ease (yes/no), chronic obstructive pulmonary disease (yes/no),
peripheral artery disease (yes/no), previous stroke (yes/no),
valvular disease (yes/no), left ventricular function (%), treat-
ment with antiaggregants, treatment with digoxin, treatment
with antiarrhythmics, treatment with angiotensin-converting
enzyme inhibitors or angiotensin receptor antagonists. The
area under the receiver operating curve (ROC) showed an
excellent discriminative capacity (0.936) to predict the prob-
ability of receiving anticoagulation. The CHA2DS2-VASc and
HASBLED scores were not independently associated with the
probability of receiving acenocoumarol.
To explore the prognostic effect of acenocoumarol in our
study population, we  performed a multivariate Cox regressionhypertension; LVH: left ventricular hypertrophy; ACE x inhibitors:
angiotensin-converting enzyme inhibitors.
model and a negative binomial regression (NBreg) including
the quartiles of PS and the CHA2DS2-VASc score for death and
recurrent hospitalizations, respectively.
For recurrent hemorrhagic events, a negative binomial
regression was used and the risk estimates were adjusted by
quartiles of the PS and HASBLED score. The risk estimation
is shown as hazard ratios (HRs) for death and incidence rate
ratios (IRRs) for recurring events. All analyses were performed
using Stata 14.1.
Results
The patients mean age was 75±10 years; 66.2% were men and
43 patients (58.1%) received acenocoumarol. The estimated
median (IQR) of glomerular ﬁltration rate, CHA2DS2-VASc
and HASBLED was 7.3 (5.4–10.2) mL/min/1.73 m2, 43–5 and 3,3,4
respectively. Table 1 shows the baseline characteristics of the
patient population.
In the anticoagulated patients, the AF was permanent
to a large extent (48% vs 6%, p < 0.001), the left atria was
more  dilated (44.7 ± 6.6 mm vs 40.7±6.6 mm,  p = 0.017) and
a higher proportion of a signiﬁcant left ventricular hypertro-
phy (≥14 mm)  (24% vs 2.9%, p = 0.01). Regarding the treatment,
the proportion of patients on antiplatelet therapy was greater
in non-anticoagulated than anticoagulated patients (54.8%
vs 7.3%, p = 0.000). Conversely, digoxin treatment was more
frequent in anticoagulated patients (23% vs 3%, p = 0.02). No
n e f r o l o g i a. 2 0 1 8;3  8(4):388–394 391
Table 2 – Ischemic events in patients with anticoagulant
treatment (OAC) and without anticoagulant treatment
(non-ACO).
Stroke OAC (n=43) Non-OAC (n=31)
Ischemic 6 1
Hemorrhagic 2 0
Fatal 1 0
Table 3 – Hemorrhagic events in patients with
anticoagulant treatment (OAC) and without
anticoagulant treatment (non-OAC).
Hemorrhages OAC (n=43) Non-OAC (n=31)
Total 24 10
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Fig. 1 – Survival curves of hemodialysis patients with atrial
ﬁbrillation according to anticoagulant treatment. OAC:  oral
anticoagulation. (cambiar en la ﬁgura ACO por OAC).
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Fig. 2 – Incidence of recurrent hospitalizations of
cardiovascular causes in patients with non-valvular atrial
ﬁbrillation on hemodialysis. OAC: oral anticoagulation.Severe 13 3
Fatal 6 0
ther differences were observed with respect to the rest of the
aseline characteristics. Anticoagulated patients presented a
edian TRT of 33.3% (IQR=15–48).
nticoagulation  and  adverse  clinical  events
uring a median follow-up of 2.4 years (IQR = 0.88–4.15), 51
68.9%) patients died, there were 125 hospitalizations due to
ll causes in 53 patients (71.6%), 65 hospitalizations due to car-
iovascular causes in 32 patients (43.2%), 16 hospitalizations
ue to stroke or bleeding in 14 patients (18.9%) and 26 hospital-
zations of ischemic causes in 18 patients (24.3%). There were
ine strokes (two hemorrhagic and seven ischemic), all were
n the group of anticoagulated patients except one ischemic
troke in a patient without anticoagulation; only one of them
ad a fatal outcome (it was an hemorrhagic stroke in an anti-
oagulated patient) (Table 2).
Regarding the episodes of bleeding, there were 34 hem-
rrhages in 24 patients (32.4%) and 16 were major bleedings
n 13 patients (17.6%). The anticoagulated patients presented
4 bleedings, of which 13 were severe and 6 fatal. The group
f patients without anticoagulation had 10 hemorrhages, of
hich 3 were severe, none was fatal (Table 3).
nticoagulation  and  mortality
n the univariate analysis, anticoagulation with aceno-
oumarol was not associated with lower mortality (2.78 vs
.01 per 10 person-year, p = 0.304), as represented by the
aplan–Meier curve (Fig. 1). In the multivariate analysis
djusting for PS and CHA2DS2-VASc, anticoagulation had a
eutral effect on survival [HR = 1, 0.76, 95% CI (0.35–1.66),
 = 0.494)].
nticoagulation  and  recurrent  hospitalizations
n the univariate analysis, anticoagulation was associated
ith a higher rate of recurrent hospitalizations due to all
auses (6.75 vs 4.39 per 10 person-year, p = 0.202), due to car-
iovascular causes (4.10 vs 1.50 for 10 persons-year, p < 0.001)
nd hospitalizations due to ischemic causes (1.77 vs 0.43 for 10
ersons-year; p = 0.003), as shown in Fig. 2. In the multivariate
nalysis, and after adjusting for PS and CHA2DS2-VASc score,(cambiar en la ﬁgura ACO por OAC).
the differences for hospitalization of all causes did not reach
statistical signiﬁcance [IRR = 2.13, 95% CI (0.78–5.86), p = 0.141].
However, for recurrent cardiovascular
hospitalizations, the excess risk attributable to antico-
agulant therapy remained signiﬁcant after the multivariate
adjustment [IRR = 3.94 CI, 95% CI (1.06–14.69), p = 0.041]. Finally,
there was also a tendency to an increased risk of repeated hos-
pitalizations of ischemic cause in anticoagulated patients [IRR
= 5.80, 95% CI (0.86–39.0), p=0.071].
Anticoagulation  and  recurrent  bleeding
There was a tendency of a higher frequency of total hem-
orrhages and also major hemorrhages in anticoagulated
patients [1.93 vs 1.11 (p = 0.113) and 1.05 vs 0.32 (p = 0.051)].
After multivariate adjustment, we observed a tendency
toward an increased risk of recurrent bleeding in the antico-
agulated patients [IRR = 4.43, 95% CI (0.94–20.81), p = 0.059].
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Regarding major bleeding, although the differences were
ostensible, these did not become statistically signiﬁcant [IRR=
P13.38, 95% CI (0.47–382.68), p < 0.129)].
Time  in  therapeutic  range  (TRT)  and  hemorrhagic  events
in anticoagulated  patients
Our anticoagulated patients presented a median TRT of 33.3%
(IQR = P15-48).
The anticoagulated patients with major bleeding had a
higher percentage of INR controls above the therapeutic range
than the anticoagulated patients without major hemorrhages;
the respective medians were 19% (IQR = 2–26%) vs 10% (IQR =
0–26%), p < 0.01.
Discussion
The beneﬁt of oral anticoagulation in patients with AF has
been demonstrated in randomized studies.2 In these trials,
end-stage renal failure has been systematically an exclusion
criterion. There is no evidence that this beneﬁt can be extrap-
olated to hemodialysis patients6–8; and, it is well known that
the risk of ischemic and hemorrhagic complications in these
patients is higher than that of the general population.2,4,6,9
In our study, which evaluated a group of patients with AF
and end-stage renal disease broadly representative of daily
clinical practice, it was observed that oral anticoagulation did
not present any beneﬁt in terms of survival. Our results are in
agreement with a meta-analysis that included 37.349 patients
of similar characteristics, in which anticoagulation did not
show any beneﬁt in mortality.4,10–15
Regarding recurrent hospitalizations, the present study
showed an increase in recurrent hospitalizations of cardio-
vascular causes, with a tendency to increase the risk of
hospitalizations due to ischemic causes. These ﬁndings are
of special relevance given that previous studies in hemodialy-
sis patients with AF receiving anticoagulation did not analyze
recurrent hospitalizations.
With respect to the risk of bleeding, in the present study we
found a signiﬁcant increase in the risk of recurrent bleeding,
which, however, did not become statistically signiﬁcant, prob-
ably because of the small sample size. Consistent with these
results, four recent meta-analysis of observational studies
suggest that warfarin should not be used routinely in patients
on hemodialysis with AF since it does not provide a beneﬁt in
mortality and strokes are not prevented signiﬁcantly however
it does increase the risk of hemorrhage in these patients.5,16–18
Our study population had a high thromboembolic risk
as determined by the CHA2DS2-VASc scale, with a median
of 4 (IQR = 3–5), so oral anticoagulation should be recom-
mended. To date, there is not enough evidence supporting
anticoagulation in these patients based on this risk scale.
Furthermore, renal failure has been shown to be an indepen-
dent risk factor for stroke.19,20 The mechanism of stroke in
patients on hemodialysis with AF is not clearly established.
It is likely that in these patients there is a greater risk of
atherothrombotic than embolic stroke.5 And, there is evi-
dence that warfarin may be associated with an increased risk;3 8(4):388–394
of calciphylaxis21,22 and accelerated vascular calciﬁcation in
hemodialysis patients.23,24
The antiaggregant treatment has not been shown to be
effective in reducing strokes of cardioembolic origin or strokes
due to systemic embolisms,25 however it is effective in pre-
venting atherothrombotic events, so it could have contributed
to the reduction of ischemic events of this origin in the popula-
tion of non-anticoagulated patients, given that many  of them
were on antiplatelet therapy (54.8% vs 7.3%, p = 0.000).
Patients who are anticoagulated in hemodialysis fre-
quently present labile INR (TRT below 60%), as reported in the
few studies in which this parameter has been analyzed.4,13,26
In this line, the recent study by Szummer et al.27 shows that
TRT is lower in patients with chronic kidney disease, and a
low TRT is associated to poor prognosis independently of renal
function. In fact, our patients had a median TRT of 33.3% (IQR =
P15–48). This ﬁnding could, in some way, be related to the poor
clinical results of anticoagulation with antivitamin K in these
patients. In the study of Limdi et al.28, advanced renal failure
is associated with an increase in the frequency of supra-
therapeutic ranges of INR and an increased risk of bleeding;
in fact, in our study, anticoagulated patients who presented
major bleeding had a higher percentage of INR controls above
the therapeutic range than anticoagulated patients without
major hemorrhages, with a median of 19% (IQR = 2–26%). com-
pared to 10% (IQR =0–26%), p < 0.01.
Unfortunately, we are unable to perform an analysis of
those who had a TRT greater than or equal to 60% compared
to the rest since there were only two patients showing opti-
mal  control, so it is not a sufﬁcient number to establish a
comparison.
Despite the inherent limitations due to the sample size,
and given that in a traditional methodological approach from
time to the ﬁrst event, the recommendations suggest to have a
minimum of 10 events for each covariate included in the mul-
tivariate model29 it was decided to use an adjustment through
a PS, with the intention to generate a model with excellent
discriminative power, generally above 0.85. In our case, the dis-
criminative capacity of the model was >0.90, which indicates
an excellent discriminative power. The adjustment made here
using a PS (to try to minimize the residual confounding biases
typical of observational studies) is in line with what is tradi-
tionally accepted.
In an attempt to increase the power of the study and
to better describe the natural history of the disease, we
decided to explore the relationship between anticoagulation
and repeated events (all events) throughout the follow-up.
With this approach, which in recent years has been used
an promoted by important research groups,30–32 we  have
recorded 125 hospitalizations for all causes and 65 hospital-
izations of cardiovascular causes, which undoubtedly increase
the power of the study and offer a more  solid risk estimates.
LimitationsThe limitations of our study are those inherent to a retrospec-
tive, observational analysis in a single center; however, the
population evaluated here is a reﬂection of the everyday clini-
cal practice that includes all patients with AF in hemodialysis
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uring a very long period, from January 2005 to October 2016,
nd with a prolonged follow-up [median follow-up of 2.4 years
IQR = 0.88–4.15)]. In addition, this is a small study with limited
ower to detect signiﬁcant differences, especially if there is a
educed number of adverse episodes. To minimize confound-
ng biases we  use an adjustment through a PS. To increase the
ower of the study, we  performed an analysis including all
he repeated events throughout the follow-up. In the present
tudy it has not been possible to perform an event analysis
n patients with optimal TRT since only two of the anticoag-
lated patients fulﬁlled this condition, which highlights the
ifﬁculty in controlling anticoagulation with dicoumarin in
hese patients.
onclusions
n the present study, oral anticoagulation with acenocoumarol
n patients on hemodialysis with AF did not increase survival,
nd it was associated with an increased risk of hospitaliza-
ions due to cardiovascular causes and there was a tendency
o increase the risk of total bleeding. New studies, preferably
rospective and in more  controlled scenarios are necessary to
eveal the usefulness of anticoagulation in these patients..
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